Abstract

The purpose of this study was to examine whether women who were treated with 17 alpha-hydroxyprogesterone caproate (17-OHPC) to prevent recurrent preterm birth experienced a change in cervical shortening over time, compared with women who were not treated. We conducted a retrospective exposure cohort study of women who were enrolled in a prematurity prevention clinic from 1999-2008 with a singleton pregnancy with > or =1 previous spontaneous preterm births (<37 weeks of gestation) who underwent > or =2 cervical length measurements by endovaginal ultrasound. Of 200 women, 105 women received treatment with 17-OHPC; 95 women did not. Women who were treated with 17-OHPC were more likely to have experienced a previous preterm birth (26.0 vs 27.8 weeks; P = .01) than those who were not treated with 17-OHPC. There was no difference in the average weekly change in cervical length among women treated with 17-OHPC, compared with those who were not, after adjustment for covariates (0.79 mm/week; 95% confidence interval, -1.18 to 2.76). There was no difference in the average weekly change in cervical length measurements over time in women who underwent 17-OHPC treatment, compared with those who were not treated.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call